Cris Lanting, Ph.D.

Medical Physicist–Audiologist (MPE)

Hereditary Hearing Loss · Cochlear Implants · Clinical Trials · Auditory Profiling

I am a Medical Physicist–Audiologist working at the intersection of clinical audiology, genetics, and auditory rehabilitation at Radboud University Medical Center (Radboudumc).

My research follows a single translational arc from identifying the genetic cause of a patient’s hearing loss, through audiological characterisation of the phenotype (‘I can hear, but I cannot understand what you say’), auditory profiling, to measuring outcomes of cochlear implantation and inner-ear therapeutics. The driving question across all projects: how does genotype shape auditory function, and how should that shape treatment?

---

Focus areas

• Hearing & Genes
• Hearing & Implants
• Clinical Trials
• Auditory Profiling
• Pediatric Audiology

---

Clinical leadership

• Expertise Center Hearing & Implants (Radboudumc) Multidisciplinary care for hearing rehabilitation at the largest implant center in the Netherlands, including cochlear and middle-ear implants; outcome evaluation and pathway optimization.

• Expertise Center Hearing & Genes (Radboudumc) Multidisciplinary diagnostics and genetic counseling for rare and hereditary hearing disorders, with a focus on previously unresolved cases combining state-of-the-art genotyping with detailed audiological phenotyping.

• DOOFNL — National Rare Hearing Disorders Network Unique national collaboration of academic ENT departments, clinical geneticists, and audiologists dedicated to solving diagnostically challenging cases of (suspected) hereditary hearing loss. DOOFNL addresses patients for whom standard clinical workup has not yielded a diagnosis, through coordinated genetic and audiological investigation across Dutch academic centers.

• ERN-CRANIO — European Reference Network Part of the EU-designated European Reference Network for Rare Craniofacial Anomalies and ENT Disorders. Provides cross-border expert consultation and structured case management for patients with complex or syndromic hearing loss across Europe.

• Pediatric audiology Complex diagnostics, etiological genetic workup, cochlear implantation trajectories, and outcome monitoring in children.

• Guidelines and consensus development Contributor to national and international consensus on implantable hearing solutions in conductive and mixed hearing loss (“Consensus Statement on Bone Conduction Devices and Active Middle Ear Implants in Conductive and Mixed Hearing Loss,” 2022).

---

Research vision

The long-term goal is a precision-audiology pipeline in which a patient’s genetic profile, audiological signature, and electrophysiological responses together inform which intervention will work — and how well. This pipeline is already operational at Radboudumc for cochlear implant candidates with characterised hereditary hearing loss. The current programme extends it in three directions: suprathreshold auditory profiling to characterise hearing beyond the threshold audiogram; inner-ear therapeutics with endpoints fit for a generation of gene therapy trials now entering Phase 1/2; and — for those we cannot yet help with curative treatment — remote and anatomy-informed tools that scale hearing healthcare to patients who cannot, or need not, readily access a clinic.

Priorities for the next five years:

• Auditory profiling — characterising suprathreshold processing of speech in noise, linking spectrotemporal modulation sensitivity to speech-in-noise outcomes across groups with varying degrees of hearing loss. In collaboration with Marc van Wanrooij (Donders Institute for Brain, Cognition and Behaviour), funded through the 2024 Donders Research Stimulation Fund, with 3 MSc and 4 BSc students involved.
• Audiological endpoints for inner-ear gene therapy — developing, validating, and standardising outcome measures for early-phase trials, where small sample sizes demand sensitive and reproducible instruments (see e.g. audiometric profiling in (Wijn et al., 2025)).
• Cisplatin ototoxicity prevention — a Phase 3 protocol for preventing cisplatin-related hearing damage in children with cancer, written in collaboration with LUMC, UMC Utrecht, Radboudumc, and Erasmus MC.
• Anatomy-based cochlear implant fitting linked to listening-effort measures — a 2025–2029 IIR-funded project (with MedEl) asking whether individualising fitting to cochlear anatomy improves neural and perceptual outcomes.
• Continued leadership within DOOFNL and ERN-CRANIO on rare hereditary hearing disorders and cross-border expertise sharing.

---

Experience

Radboud University Medical Center, Nijmegen Medical Physics Expert (MPE) – Audiologist (2018–present) Clinical audiology (adult and pediatric), hereditary hearing loss, cochlear implantation, Phase 1/2 clinical trials, supervision of PhD candidates and trainees.

See full history

---

Education

University of Groningen — Ph.D. in Biomedical Sciences (2005–2010) Thesis: Functional Magnetic Resonance Imaging of Tinnitus. Defence: March 2010. Download PDF

See full list

---

PhD supervision

Co-promotor for 9 PhD candidates (6 ongoing, 3 completed) across hereditary hearing loss, cochlear implantation outcomes, anatomy-based fitting, and remote audiology. Scientific leadership is reflected in last or shared-last authorship on candidate publications. Current projects include gene therapy trial readiness, anatomy-based fitting and listening effort (IIR/MedEl 2025–2029), and CI outcome prediction in genetically characterised populations (IIR/Cochlear 2020–2024, completed). Also supervising one medical physicist in training and ongoing MSc thesis projects.

See full list

---

Grants & awards

• 2025–2029: IIR Grant with MedEl — Anatomy Based Fitting and neural correlates of listening effort (PhD project) — PI
• 2024: Donders Research Stimulation Fund — Ear and Hearing Focus group
• 2024: Donders Research Stimulation Fund — Collaboration with Marc van Wanrooij on auditory profiling
• 2020-2024: IIR Grant with Cochlear Ltd — Genetic hearing loss and cochlear implantation outcomes (PhD project) — co-applicant
• Pending: ZonMW research grant — under revision

See full list

---

Committees & activities

• Chair, NVKF Knowledge Agenda 2.0 (2025–2029)
• Member, NVKF Commissie Wetenschap & Innovatie
• Editor, Audiologieboek.nl
• Member, National Scientific Committee European Symposium on Pediatric Cochlear Implantation (ESPCI) 2023 Rotterdam
• Member, National Scientific Committee Inner Ear Biology (IEB) 2026 Utrecht
• Scientific audiology advisor, ENT Clinical
• Active peer reviewer for international journals in audiology, genetics, and hearing research (Web of Science / Publons)

See full list

---

Teaching

• Lecturer and guest lecturer in audiology, otogenetics, and auditory neuroscience (Radboudumc, Radboud University, University of Groningen).
• Member of PhD examination committees (opponent / leescommissie) at national and international institutions.
• Invited speaker at international conferences, including ESPCI Rotterdam (2023) and University of Oldenburg.

See full teaching history

---

Certifications

• 2024: Leergang Begeleiden van Promovendi — Supervising PhDs, Radboudumc
• 2023: Good Clinical Practice (GCP) for Site Staff — ISO 14155:2020, Cochlear Academy
• 2022: ICH Good Clinical Practice (GCP) E6(R2)

See full list

---

Selected publications

1. Lanting, C., Robijn, S., Nieratschker, M., Galetzka, C., Meis, A., Rommelspacher, H., Ahoud-Schoenmakers, S., Lackner, E., Zeitlinger, M., Bauer, M., Arnoldner, C., Pennings, R., & Schlingensiepen, R. (2025). Assessment of Safety, Tolerability, Pharmacokinetics, and Volume-Dependent Conductive Hearing Loss in Healthy Volunteers: First-in-Human, Open-Label, Placebo-Controlled Study of a Single Intratympanic Injection of AC102. Otology & Neurotology, 46(8), 884–894. https://doi.org/10.1097/MAO.0000000000004568

   First-in-human Phase 1 trial of intratympanic AC102 for sudden sensorineural hearing loss, establishing safety, tolerability, and pharmacokinetics.
2. Wasmann, J.-W. A., Huinck, W. J., & Lanting, C. P. (2024). Remote Cochlear Implant Assessments: Validity and Stability in Self-Administered Smartphone-Based Testing. Ear and Hearing, 45(1), 239–249. https://doi.org/10.1097/AUD.0000000000001422

   Validates a self-administered, smartphone-based remote fitting protocol for cochlear implant users — reliable, stable, and directly deployable in routine care.
3. Colbert, B. M., Lanting, C., Smeal, M., Blanton, S., Dykxhoorn, D. M., Tang, P.-C., Getchell, R. L., Velde, H., Fehrmann, M., Thorpe, R., Chapagain, P., Elkhaligy, H., Kremer, H., Yntema, H., Haer-Wigman, L., Redfield, S., Sun, T., Bruijn, S., Plomp, A., … Liu, X. Z. (2024). The Natural History and Genotype–Phenotype Correlations of TMPRSS3 Hearing Loss: An International, Multi-Center, Cohort Analysis. Human Genetics, 143(5), 721–734. https://doi.org/10.1007/s00439-024-02648-3

   International multi-centre natural history study of TMPRSS3-related hearing loss, providing the prognostic data needed for counselling and trial eligibility.
4. Velde, H. M., Homans, N. C., Goedegebure, A., Lanting, C. P., Pennings, R. J. E., & Kremer, H. (2023). Analysis of Rotterdam Study Cohorts Confirms a Previously Identified RIPOR2 In-Frame Deletion as a Prevalent Genetic Factor in Phenotypically Variable Adult-Onset Hearing Loss (DFNA21) in the Netherlands. Journal of Medical Genetics, 60(11), 1061–1066. https://doi.org/10.1136/jmg-2023-109146

   Population-scale replication of the RIPOR2 finding (above) in the Rotterdam Study, confirming prevalence and supporting routine genetic screening.
5. Lanting, C., Snik, A., Leijendeckers, J., Bosman, A., & Pennings, R. (2022). Genetic Hearing Loss Affects Cochlear Processing. Genes, 13(11), 1923. https://doi.org/10.3390/genes13111923

   Directly links genotype to cochlear processing and auditory phenotype, anchoring the genotype-to-outcome research narrative.
6. Wasmann, J.-W. A., Lanting, C. P., Cris P. Lanting, Huinck, W. J., Mylanus, E. A. M., van der Laak, J. W. M., Govaerts, P., De Wet Swanepoel, Moore, D. R., & Barbour, D. L. (2021). Computational Audiology: New Approaches to Advance Hearing Health Care in the Digital Age. Ear and Hearing. https://doi.org/10.1097/aud.0000000000001041

   Coins the term Computational Audiology and defines the framework for applying digital and computational approaches to hearing health care.
7. De Bruijn, S. E., Smits, J. J., Liu, C., Lanting, C. P., Beynon, A. J., Blankevoort, J., Oostrik, J., Koole, W., De Vrieze, E., Cremers, C. W. R. J., Cremers, F. P. M., Roosing, S., Yntema, H. G., Kunst, H. P. M., Zhao, B., Pennings, R. J. E., & Kremer, H. (2021). A RIPOR2 In-Frame Deletion Is a Frequent and Highly Penetrant Cause of Adult-Onset Hearing Loss. Journal of Medical Genetics, 58(2), 96–104. https://doi.org/10.1136/jmedgenet-2020-106863

   Establishes RIPOR2 as the most prevalent cause of adult-onset autosomal dominant hearing loss in the Netherlands (>90% penetrance); replicated at population scale below.
8. Chen, T., Rohacek, A. M., Caporizzo, M., Nankali, A., Smits, J. J., Oostrik, J., Lanting, C. P., Kücük, E., Gilissen, C., van de Kamp, J. M., Pennings, R. J. E., Rakowiecki, S. M., Kaestner, K. H., Ohlemiller, K. K., Oghalai, J. S., Kremer, H., Prosser, B. L., & Epstein, D. J. (2021). Cochlear Supporting Cells Require GAS2 for Cytoskeletal Architecture and Hearing. Developmental Cell, 56(10), 1526–1540.e7. https://doi.org/10.1016/j.devcel.2021.04.017

   Links GAS2 to cochlear supporting-cell cytoskeletal integrity — first mechanistic basis connecting this gene to human hereditary hearing loss.

For a complete list of publications, see Publications.

---

Digital presence

• ORCID 0000-0001-9397-7766
• Google Scholar
• Web of Science / Publons
• LinkedIn

Last updated: Mar 2026